37 completed. 37 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 37 |
| Phase 2 | 6 | Completed 6 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of N115 on Coughing in IPF Patients 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Cellular Sciences, inc. | 50 | 2023-08-15 | 2024-08-07 |
| A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) BI 1015550, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Boehringer Ingelheim | 1177 | 2022-10-06 | 2025-10-20 |
| Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Completed | United Therapeutics | 597 | 2022-09-12 | 2026-10-15 |
| Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital cyclosporine - COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome | Phase 3 | Completed | Alexandria University | 66 | 2022-01-03 | 2025-05-14 |
| Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Completed | United Therapeutics | 598 | 2021-06-01 | 2026-05-05 |
| Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough Morphine Sulfate, Placebo oral tablet - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Royal Brompton & Harefield NHS Foundation Trust | 44 | 2020-12-17 | 2026-05-07 |
| Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial N-acetyl cysteine, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Fernando J Martinez | 202 | 2020-12-17 | 2026-03-20 |
| A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis Double-Blind Placebo, Double-Blind Rituximab - Scleroderma, Systemic, Skin Sclerosis | Phase 2 / Phase 3 | Completed | Tokyo University | 56 | 2017-12-04 | 2020-02-18 |
| Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Hoffmann-La Roche | 60 | 2017-10-23 | 2020-11-20 |
| The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation Omacor, Placebo Oral Capsule - Kidney Transplantation | Phase 3 | Completed | Joe Chan | 174 | 2017-09-01 | 2025-04-03 |
| Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases Rituximab, Placebo of Rituximab, Mycophenolate Mofetil - Lung Disease, Interstitial | Phase 3 | Completed | University Hospital, Tours | 122 | 2017-01-20 | 2025-12-30 |
| Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Nintedanib, Placebo, Sildenafil - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Boehringer Ingelheim | 274 | 2016-06-30 | 2019-01-11 |
| Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis ART-123, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Asahi Kasei Therapeutics Corporation | 74 | 2016-05-01 | 2019-01-18 |
| Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Cyclophosphamide, Placebo, Corticosteroid (prednisolone) - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 120 | 2015-12-01 | 2022-06-30 |
| Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Rituximab, Cyclophosphamide - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Royal Brompton & Harefield NHS Foundation Trust | 104 | 2014-11-01 | 2021-10-07 |
| Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Matching Placebo, Nintedanib - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Boehringer Ingelheim | 113 | 2013-11-26 | 2018-04-17 |
| Rituximab in Systemic Sclerosis Rituximab, Placebo (NaCl) - Systemic Sclerosis | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 22 | 2013-04-09 | 2025-11-20 |
| Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease Cyclophosphamide, Placebo - Systemic Sclerosis, Scleroderma | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 40 | 2013-01-14 | 2025-09-12 |
| Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis Nintedanib - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Boehringer Ingelheim | 752 | 2012-06-06 | 2022-03-25 |
| Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Pirfenidone, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Genentech, Inc. | 555 | 2011-06-01 | 2017-04-05 |
Showing 20 of 37. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (26) · Lung Diseases, Interstitial (9) · Scleroderma, Systemic (5) · Scleroderma, Diffuse (4) · Fibrosis (3) · Connective Tissue Diseases (2) · Lung Diseases (2) · Arthritis (1) · Autoimmune Diseases (1) · Bronchiectasis (1) · COVID-19 (1) · Collagen Diseases (1) · Cough (1) · Cystic Fibrosis (1)
Respiratory Tract Diseases (36) · Lung Diseases (35) · Lung Diseases, Interstitial (28) · Pathological Conditions, Signs and Symptoms (20) · Pathologic Processes (19) · Fibrosis (16) · Skin and Connective Tissue Diseases (7) · Skin Diseases (6) · Connective Tissue Diseases (5) · Musculoskeletal Diseases (2) · Respiration Disorders (2) · Signs and Symptoms (2) · Bronchial Diseases (1) · Cardiovascular Diseases (1)
nintedanib (5) · pirfenidone (5) · Bosentan (4) · Cyclophosphamide (4) · Acetylcysteine (3) · Rituximab (3) · Sildenafil Citrate (2) · treprostinil (2) · ART123 (1) · Adrenal Cortex Hormones (1) · BI 1015550 (1) · Control Groups (1) · Cyclosporine (1) · Fatty Acids, Omega-3 (1) · Imatinib Mesylate (1)
Boehringer Ingelheim (6) · Actelion (4) · Genentech, Inc. (4) · Assistance Publique - Hôpitaux de Paris (3) · Duke University (2) · Royal Brompton & Harefield NHS Foundation Trust (2) · United Therapeutics (2) · Alexandria University (1) · Asahi Kasei Therapeutics Corporation (1) · Cellular Sciences, inc. (1) · Daniels, Craig E., M.D. (1) · Fernando J Martinez (1) · Hoffmann-La Roche (1) · InterMune (1) · Joe Chan (1)
United States (19) · France (12) · Canada (8) · Germany (8) · United Kingdom (8) · Italy (7) · Japan (7) · Australia (6) · Belgium (6) · Spain (6) · Chile (5) · Mexico (5) · Netherlands (5) · South Korea (5) · China (4)
Imre Noth, MD (3) · Fernando Martinez, MD (2) · Ganesh Raghu, MD (2) · Isabelle Leconte (2) · James Loyd, MD (2) · Jay Ryu, MD (2) · Jesse Roman, MD (2) · Joe Lasky, MD (2) · Kevin Anstrom, PhD (2) · Kevin Brown, MD (2) · Rob Kaner, MD (2) · Talmadge King, MD (2)
PMID 28388260, PMID 26835133, PMID 35688625, PMID 37391667, PMID 26968970, PMID 27708114, PMID 30072107, PMID 30116539, PMID 30472023, PMID 31047956, PMID 31153107, PMID 31401786, PMID 31914963, PMID 33434107, PMID 33902584, PMID 21571362, PMID 24834811, PMID 24836310, PMID 25890798, PMID 26111071, PMID 26400368, PMID 27672117, PMID 28039616, PMID 28526798, PMID 30176872, PMID 30729456, PMID 30971229, PMID 32217654, PMID 33239000, PMID 42548365, PMID 42776606, PMID 16306520, PMID 16790698, PMID 17717203, PMID 17901413, PMID 17901414, PMID 18641099, PMID 19679600, PMID 19860915, PMID 19892673, PMID 20007927, PMID 20484178, PMID 20506355, PMID 21474646, PMID 21547897, PMID 22156609, PMID 22607134, PMID 22986377, PMID 24836309, PMID 24836312
2015 (2), U10HL080413 (2), 2016 (1), 2019 (1), U01HL060839 (1), U24HL145265 (1)